Harrisons Manual of Oncology 2/E

896 Pages·2013·16.34 MB·English

by  Bruce Chabner

2nd Edition
TM
M A N U A L O F
O n c O l O g y
NOTICE
Medicine is an ever-changing science. As new research and clinical
experience broaden our knowledge, changes in treatment and drug
therapy are required. The authors and the publisher of this work have
checked with sources believed to be reliable in their efforts to provide
information that is complete and generally in accord with the standards
accepted at the time of publication. However, in view of the possibility
of human error or changes in medical sciences, neither the authors
nor the publisher nor any other party who has been involved in the
preparation or publication of this work warrants that the information
contained herein is in every respect accurate or complete, and they
disclaim all responsibility for any errors or omissions or for the results
obtained from use of the information contained in this work. Readers
are encouraged to confirm the information contained herein with other
sources. For example and in particular, readers are advised to check the
product information sheet included in the package of each drug they
plan to administer to be certain that the information contained in this
work is accurate and that changes have not been made in the recom-
mended dose or in the contraindications for administration. This
recommendation is of particular importance in connection with new
or infrequently used drugs.
2nd Edition
TM
M A N U A L O F
O n c O l O g y
Bruce A. Chabner, MD
Professor of Medicine
Harvard Medical School
Director of Clinical Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Dan L. Longo, MD
Professor of Medicine
Harvard Medical School
Senior Physician
Brigham and Women’s Hospital
Deputy Editor
New England Journal of Medicine
Boston, Massachusetts
New York Chicago San Francisco Athens London Madrid
Mexico City Milan New Delhi Singapore Sydney Toronto
Copyright © 2014 by McGraw-Hill Education. All rights reserved. Except as
permitted under the United States Copyright Act of 1976, no part of this
publication may be reproduced or distributed in any form or by any means, or stored
in a database or retrieval system, without the prior written permission of the publisher,
with the exception that the program listings may be entered, stored, and executed in a
computer system, but they may not be reproduced for publication.
ISBN: 978-0-07-179326-1
MHID: 0-07-179326-7
The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-179325-4,
MHID: 0-07-179325-9.
eBook conversion by codeMantra
Version 1.0
All trademarks are trademarks of their respective owners. Rather than put a trademark
symbol after every occurrence of a trademarked name, we use names in an editorial fashion
only, and to the benefit of the trademark owner, with no intention of infringement of the
trademark. Where such designations appear in this book, they have been printed with
initial caps.
McGraw-Hill Education eBooks are available at special quantity discounts to use as
premiums and sales promotions or for use in corporate training programs. To contact a
representative, please visit the Contact Us page at www.mhprofessional.com.
All trademarks or copyrights mentioned herein are the possession of their respective
owners and McGraw-Hill Education makes no claim of ownership by the mention of
products that contain these marks.
TERMS OF USE
This is a copyrighted work and McGraw-Hill Education and its licensors reserve all
rights in and to the work. Use of this work is subject to these terms. Except as permit-
ted under the Copyright Act of 1976 and the right to store and retrieve one copy of
the work, you may not decompile, disassemble, reverse engineer, reproduce, modify,
create derivative works based upon, transmit, distribute, disseminate, sell, publish or
sublicense the work or any part of it without McGraw-Hill Education’s prior consent.
You may use the work for your own noncommercial and personal use; any other use
of the work is strictly prohibited. Your right to use the work may be terminated if you
fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND
ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE
ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE
OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION
THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR
OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRAN-
TIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
McGraw-Hill Education and its licensors do not warrant or guarantee that the
functions contained in the work will meet your requirements or that its operation will
be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall
be liable to you or anyone else for any inaccuracy, error or omission, regardless of
cause, in the work or for any damages resulting therefrom. McGraw-Hill Education
has no responsibility for the content of any information accessed through the work.
Under no circumstances shall McGraw-Hill Education and/or its licensors be liable
for any indirect, incidental, special, punitive, consequential or similar damages that
result from the use of or inability to use the work, even if any of them has been advised
of the possibility of such damages. This limitation of liability shall apply to any claim
or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.
CONTENTs
Contributors ................................................. xi
Preface ..................................................... xxi
INTRODUCTION Considerations for Cancer Pharmacotherapy
SeCTION 1 Classes of Drugs
1 Antimetabolites: Nucleoside
and Base Analogs .........................................11
Bruce A. Chabner
2 Antifolates ..............................................29
Bruce A. Chabner
3 The Taxanes, Vinca Alkaloids,
and Their Derivatives ......................................36
Bruce A. Chabner
4 Topoisomerase Inhibitors: Camptothecins, Anthracyclines,
and etoposide ...........................................48
Bruce A. Chabner
5 Adduct-Forming Agents: Alkylating
Agents and Platinum Analogs ................................62
Bruce A. Chabner
6 Immunomodulatory Drugs and Proteasome Inhibitors .............72
Anuj Mahindra, Hamza Mujagic, Bruce A. Chabner
7 Natural Products: Bleomycin
and Trabectedin ..........................................83
Bruce A. Chabner
8 l-Asparaginase ...........................................89
Bruce A. Chabner
9 Differentiating Agents .....................................92
Bruce A. Chabner
10 Molecular Targeted Drugs ..................................97
Benjamin Izar, Jeffrey W. Clark, Bruce A. Chabner
SeCTION 2 Hormonal Agents
11 Antiestrogens ...........................................133
Tanja Badovinac Crnjevic, Paul E. Goss
v
vi CONTENTs
12 Antiandrogen Therapy ....................................143
Bruce A. Chabner
SeCTION 3 Section Biological Response Modifiers
13 Interferons .............................................147
Dan L. Longo
14 Cytokines, Growth Factors, and Immune-Based
Interventions ...........................................152
Dan L. Longo
15 Monoclonal Antibodies
in Cancer Treatment ......................................173
Dan L. Longo
SeCTION 4 Supportive Care
16 Osteoclast-Targeted Therapy:
Bisphosphonates and Denosumab ...........................193
Matthew R. Smith
17 Febrile Neutropenia ......................................197
Stephen M. Carpenter, Fabrizio Vianello, Mark C. Poznansky
18 Anemia ................................................207
Zuzana Tothova, James Bradner
19 Cancer and Coagulopathy .................................217
Rachel P.G. Rosovsky
20 Metabolic emergencies in Oncology..........................243
Ephraim Paul Hochberg
21 Pain Management .......................................264
Juliet Jacobsen, Vicki Jackson
22 Comprehensive end-of-Life Care ............................271
Jennifer Shin, Jennifer Temel
23 Depression, Anxiety, and Fatigue ............................279
Carlos G. Fernandez-Robles, William F. Pirl
SeCTION 5 Myeloid Malignancy
24 Acute Myeloid Leukemia ..................................289
Amir T. Fathi
25 Myelodysplastic Syndromes ...............................300
Eyal C. Attar
26 Myeloproliferative Neoplasms ..............................314
Jerry L. Spivak
CONTENTs vii
27 Chronic Myeloid Leukemia ................................337
Karen Ballen
SeCTION 6 Lymphoid Malignancy
28 Acute Lymphoblastic Leukemia
and Lymphoma .........................................341
James W. Fraser, Janet E. Murphy, Eyal C. Attar
29 Chronic Lymphocytic Leukemia/
Small Lymphocytic Lymphoma ..............................357
Philip C. Amrein
30 Plasma Cell Disorders ....................................375
Noopur Raje, Dan L. Longo
31 Diffuse Large B-Cell Lymphoma .............................394
Jennifer Gao, Ephraim Paul Hochberg
32 Hodgkin’s Disease .......................................406
Dan L. Longo
33 Follicular Lymphoma .....................................421
Amy Sievers, Ann LaCasce
34 Mantle Cell Lymphoma ....................................433
Dan L. Longo
35 Peripheral T-cell Lymphomas ...............................436
Jeffrey A. Barnes, Jeremy S. Abramson
36 Uncommon B-Cell Lymphomas .............................455
Jeremy S. Abramson, Jeffrey A. Barnes
SeCTION 7 High-Dose Therapy and Bone Marrow Transplant
37 Immunology of Hematopoietic Stem Cell Transplantation .........475
Srinivas Viswanathan, Yi-Bin Chen
38 Overview of Clinical Bone
Marrow Transplantation ...................................486
Sarah Nikiforow, Thomas R. Spitzer
SeCTION 8 GU Oncology
39 Renal Cell Carcinoma ....................................501
M. Dror Michaelson
40 Localized Prostate Cancers ................................511
Jason A. Efstathiou, Phillip J. Gray, Douglas M. Dahl
41 Metastatic Prostate Cancer ................................521
Matthew R. Smith
viii CONTENTs
42 Bladder Cancer .........................................527
Richard J. Lee
43 Testicular Cancer ........................................536
Timothy Gilligan
SeCTION 9 GI Oncology
44 esophageal and Gastric Cancer ............................545
Lawrence S. Blaszkowsky
45 Pancreatic Cancer .......................................558
Jeffrey W. Clark
46 Cholangiocarcinoma and
Gallbladder Cancers .....................................570
Janet E. Murphy, Andrew X. Zhu
47 Colon Cancer ..........................................580
David P. Ryan
48 Rectal Cancer ...........................................589
Theodore S. Hong
49 Anal Cancer ............................................597
Jennifer Wo
SeCTION 10 Thoracic Oncology
50 Malignant Mesothelioma ..................................611
Lee M. Krug, Pasi A. Jänne
51 Non-Small Cell Lung Cancer ...............................623
Justin F. Gainor, Jeffrey A. Engelman
52 Small Cell Lung Cancer ...................................640
Anna F. Farago, Rebecca Suk Heist
53 Thymoma ..............................................649
Panos Fidias
SeCTION 11 GYN Oncology
54 Ovarian Cancer ..........................................663
Richard T. Penson
55 Primary Squamous Carcinoma of the Uterine Cervix: Diagnosis
and Management ........................................678
Olivia Foley, Marcela G. del Carmen
56 Uterine Cancer .........................................685
Don S. Dizon
CONTENTs ix
SeCTION 12 Breast Cancer
57 Breast Oncology: Clinical Presentation and Genetics .............695
Amy Comander, Tessa Cigler, Paula D. Ryan
58 Localized Breast Cancer ..................................706
Beverly Moy
59 Metastatic Breast Cancer ..................................713
Steven J. Isakoff
SeCTION 13 Melanoma
60 Melanoma .............................................729
Ryan J. Sullivan, Krista Rubin, Donald Lawrence
SeCTION 14 Sarcoma
61 Soft Tissue and Bone Sarcomas ............................747
Edwin Choy, Sam S. Yoon, Francis J.
Hornicek, Thomas F. DeLaney
SeCTION 15 Brain Tumors
62 Primary Brain Tumors .....................................773
Andrew S. Chi
63 Metastatic Brain Tumors ..................................787
April F. Eichler
64 Paraneoplastic Neurologic Syndromes ........................797
Jorg Dietrich
SeCTION 16 Endocrine Tumors
65 Thyroid Cancer ..........................................813
Lori J. Wirth, Tito Fojo
66 Adrenocortical Cancer ....................................823
Tito Fojo
SeCTION 17 Head and Neck Cancer
67 Head and Neck Cancer ....................................831
Lori J. Wirth, Paul M. Busse, Daniel Deschler
Index .....................................................849